TD Cowen downgrades Lantheus stock to hold on Curium deal view
TD Cowen downgraded Lantheus Holdings (LNTH) to Hold from Buy and cut its price target to $102.50 from $110.00. Analyst Tara Bancroft said the Curium deal is fair and sees >50% odds of most contingent value milestones, but less optimism on the top PSMA PET tier. The stock trades near $102.03. Separately, the FDA issued a Complete Response Letter for LNTH-2501.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the rating and price-target reset, plus the emphasis on which milestones are more versus less likely (including the PSMA PET highest tier). The referenced FDA Complete Response Letter adds additional downside risk to near-term sentiment.
Market read
A sell-side downgrade with a cut to the price target, anchored to deal valuation and milestone execution probabilities, alongside an FDA CRL overhang.
What to watch
The article also notes an FDA Complete Response Letter for LNTH-2501 due to third-party manufacturing conditions, which could be a larger near-term catalyst than the Curium milestone probability framing.
Background
TD Cowen frames its downgrade around how much the Curium deal’s expected benefits are already reflected in Lantheus’ valuation, while also discussing contingent value milestone odds.
Ticker impact
TD Cowen downgraded Lantheus to Hold, cut its price target to $102.50, and tied the view to the Curium deal and milestone probabilities.
Near-term downside bias versus prior Buy stance, with volatility risk around FDA and deal-milestone expectations.
The article provides a concrete analyst action (rating and PT change) plus a thesis on contingent milestones, but it does not add new deal terms; it also references an FDA CRL as additional overhang.
Market effects
Reinforces that PSMA PET and PET diagnostic manufacturing readiness can dominate valuation for imaging-kit developers.
No clear regional spillover beyond US biotech/PET diagnostics sentiment.
Limited; deal and FDA manufacturing issues are US-centric but can affect global investor risk appetite for PET diagnostics.
Counterpoint
Curium synergies are described as having little overlap, so the Hold call may underweight execution risk already priced in and overemphasize valuation rather than pipeline probability.
Key entities
- companyLantheus Holdings
Subject of the downgrade to Hold and price-target reduction, with deal and FDA manufacturing issues highlighted.
- companyCurium
Counterparty in the merger deal whose synergies and milestone structure are central to the analyst’s thesis.
- regulatorU.S. Food and Drug Administration
Issued a Complete Response Letter for LNTH-2501, citing unresolved manufacturing-related conditions at a third-party facility.
